Silence Therapeutics PLC Total Assets
Silence Therapeutics PLC total assets. Based on the latest financial reports, Silence Therapeutics PLC (SLN) holds total assets worth $106.41 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Silence Therapeutics PLC stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Silence Therapeutics PLC (1995–2025)
Total assets of Silence Therapeutics PLC from 1995 to 2025. This chart illustrates how Silence Therapeutics PLC's total assets have evolved over time, based on quarterly financial data. See SLN live share price for real-time trading data and today's change.
Silence Therapeutics PLC - Asset Composition Analysis
Silence Therapeutics PLC Total Assets Breakdown (December 2025)
Silence Therapeutics PLC total assets breakdown as of December 2025. Silence Therapeutics PLC's total assets of $106.41 Million consist of 90.3% current assets and 9.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.6% |
| Accounts Receivable | $24.61 Million | 18.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $288.00K | 0.2% |
| Goodwill | $10.62 Million | 8.1% |
Asset Composition Trend (1995–2025)
This chart illustrates how Silence Therapeutics PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Silence Therapeutics PLC current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Silence Therapeutics PLC's current assets represent 90.3% of total assets in 2025, a decrease from 99.9% in 1995.
- Cash Position: Cash and equivalents constituted 8.6% of total assets in 2025, down from 41.0% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 1995.
- Asset Diversification: The largest asset category is accounts receivable at 18.7% of total assets.
Silence Therapeutics PLC Competitors by Total Assets
Key competitors of Silence Therapeutics PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Silence Therapeutics PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.42 | 10.06 | 4.52 |
| Quick Ratio | 7.42 | 10.06 | 4.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $81.57 Million | $133.78 Million | $64.73 Million |
Silence Therapeutics PLC - Advanced Valuation Insights
This section examines the relationship between Silence Therapeutics PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.12 |
| Latest Market Cap to Assets Ratio | 6.41 |
| Asset Growth Rate (YoY) | -18.8% |
| Total Assets | $131.44 Million |
| Market Capitalization | $842.19 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Silence Therapeutics PLC's assets at a significant premium (6.41x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Silence Therapeutics PLC's assets decreased by 18.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Silence Therapeutics PLC (1995–2025)
The table below shows the annual total assets of Silence Therapeutics PLC from 1995 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $131.44 Million | -18.79% |
| 2024-12-31 | $161.85 Million | +71.23% |
| 2023-12-31 | $94.53 Million | -12.07% |
| 2022-12-31 | $107.50 Million | +11.75% |
| 2021-12-31 | $96.19 Million | +11.89% |
| 2020-12-31 | $85.97 Million | +86.58% |
| 2019-12-31 | $46.08 Million | +18.50% |
| 2018-12-31 | $38.88 Million | -29.31% |
| 2017-12-31 | $55.01 Million | -1.41% |
| 2016-12-31 | $55.79 Million | -9.34% |
| 2015-12-31 | $61.55 Million | +106.73% |
| 2014-12-31 | $29.77 Million | +1.61% |
| 2013-12-31 | $29.30 Million | +71.60% |
| 2012-12-31 | $17.07 Million | -48.94% |
| 2011-12-31 | $33.44 Million | -1.53% |
| 2010-12-31 | $33.96 Million | +208.86% |
| 2009-12-31 | $10.99 Million | -23.54% |
| 2008-12-31 | $14.38 Million | -26.18% |
| 2007-12-31 | $19.48 Million | +16.28% |
| 2006-12-31 | $16.75 Million | -2.45% |
| 2005-12-31 | $17.17 Million | +438.31% |
| 2004-12-31 | $3.19 Million | -50.84% |
| 2003-12-31 | $6.49 Million | -23.57% |
| 2002-12-31 | $8.49 Million | -12.20% |
| 2001-12-31 | $9.67 Million | -20.10% |
| 2000-12-31 | $12.10 Million | +11.95% |
| 1999-12-31 | $10.81 Million | +173.90% |
| 1998-12-31 | $3.95 Million | -25.16% |
| 1997-12-31 | $5.27 Million | -22.51% |
| 1996-12-31 | $6.81 Million | +122.27% |
| 1995-12-31 | $3.06 Million | -- |
About Silence Therapeutics PLC
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated… Read more